Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

Sartor A. O., Oudard S., Ozguroglu M., Hansen S., Machiels J. H., Shen L., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI-Expanded) identifier